Apheon has entered exclusive negotiations to acquire a majority stake in Teknimed, a French manufacturer specializing in orthopedic bone cements and biomaterials. The deal, reported by PE Hub, positions Apheon to expand its footprint in the medical device sector through Teknimed's established product portfolio and global distribution network.

Teknimed operates a fully integrated business model encompassing in-house formulation, product development, manufacturing and distribution. The company supplies approximately 280 OEMs and distributors across more than 80 countries, giving it significant market penetration in orthopedic applications. This global reach provides Apheon with immediate international scale in the growing biomaterials space.

The acquisition aligns with Teknimed's own strategy of pursuing strategic deals to complement organic growth. By partnering with Apheon, the company gains access to private equity resources while maintaining its independent positioning in the orthopedic market. The move reflects increasing consolidation in medical device manufacturing.

The transaction remains in negotiation phase, with terms and valuation undisclosed. If completed, this would mark Apheon's entry into orthopedic biomaterials, a sector seeing steady demand driven by aging populations and joint replacement procedures.